CCL20 levels (pg/ml) significantly increased in early-stage tumor than in benign cases (median [IQR], 53.02 [22.97–93.43] and 25.64 [13.59–39.32], p=0.045, respectively) (Figure 3). The gene discussed is CCL20; the disease is neoplasm.